Morningstar, Inc. - February 9, 2026
The Best Biotech Stocks to Buy
Plus: What investors need to know about the market’s wild ride,...
 Morning DigestTori Brovet These 5 undervalued biotechnology stocks look attractive today. 
ADVERTISEMENT  Editor's Picks  Jobs data is back on deck, CPI ahead, and Coinbase reports earnings amid crypto winter warnings. Tom Lauricella  Make tax time easier by getting your documents and your investments in order. Tori Brovet  Fidelity Contrafund’s retiring manager showed how long-term stock-picking success is still possible. Robby Greengold  What investors need to know about the market’s wild ride. Sarah Hansen, Rachel Schlueter Investing Insights Even with its recent dip, gold’s run looks impressive, but decades of data show why performance-chasing can undermine long-term returns. Allan Roth Funds from Dimensional, American Century, and Diamond Hill are among the winners. Gabe Alpert Hims’ new product could throw a curveball at the Wegovy pill’s trajectory. Keonhee Kim Easing inflationary pressures, shifting consumer trends, and new leadership could support a recovery. Michael Field, Susan Dziubinski, Jess Bebel With improving customer metrics and diminished capital spending, here’s what we think of Verizon. Michael Hodel The income-focused pick under Morningstar’s coverage had a big dividend increase. Frank Lee After shutdown-related delays, the January jobs and inflation reports will be released. Frank Lee More New Stock Analyst Reports Atlassian (TEAM) reported fiscal second-quarter results that once again easily topped guidance, with revenue up 23% year over year to $1.586 billion and non-GAAP operating margin of 27.1%, versus the high end of guidance at $1.539 billion and 24.5%, respectively. Cloud revenue grew 26% year over year to $1.067 billion, while data center grew 20% to $436 million and marketplace grew 8% to $84 million. All units were ahead of our expectations. AI data points are clearly favorable and create a stark disconnect from the all-encompassing software selloff. New Fund Analyst Reports Strong execution and a process whose incremental advantages add up make Baird Short-Term Bond (BSBSX) a top choice in the short-term bond Morningstar Category. Baird’s 10-person taxable bond management team may not be flashy, but its members excel as a group. The Tools You Need to Invest Like an Analyst Stay connected:
|
Unsubscribe from this newsletter. Or update your email preferences.
© 2026 Morningstar, Inc. All Rights Reserved. 22 W. Washington St. Chicago, IL 60602
